Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.
|Articles|April 21, 2003
APhA changes name, endorses unit-of-use
As the American Pharmaceutical Association became the American Pharmacists Association, delegates to the group's annual meeting endorsed unit-of-use drug packaging.
Advertisement
Advertisement
Related to this article
Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech
3
Generic Drug Costs Burdening Patients as Much as Brand Name Options
4
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
5